Patent ID: 11891447
Assignee: NATIONAL TAIWAN UNIVERSITY
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method for treating cancer, comprising:
administering to a subject in need thereof an effective amount of a CD14 antagonist, wherein the subject is a human subject having cancer;
wherein the CD14 antagonist is effective in reducing stemness of cancer stem cells (CSCs) in the human subject having cancer;
wherein the human subject having cancer has an elevated level of CD14, an elevated level of programmed death ligand-1 (PDL1), and an elevated level of CD44, as compared to a control human subject not having cancer;
wherein the cancer is lung cancer;
wherein the CD14 antagonist is an anti-CD14 antibody;
wherein the anti-CD14 antibody is an antigen-binding fragment thereof; and
wherein the anti-CD14 antibody comprises six complementarity determining regions (CDRs) of anti-hCD14-IgA2 antibody, clone D3B8.